Biotest AG — Earnings Release 2016

Aug 11, 2016

Biotest AG.

Conference Call H1 201611 August 2016

Disclaimer

• • This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and thus are subject to risks and elements of uncertainty that could result in deviation of actual developments from expected developments.
• • The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.
• • All comparative figures relate to the corresponding last year´s period, unless stated otherwise.

Biotest Group: H1 2016 at a glance

• • Sales in H1 2016 up by 6.4% to €306.1 m vs. €287.7 m in previous year period Increase largely attributable to an increase in volume in almost all geographic regions
• • H1 2016 EBIT increased to €18.2 m vs. €2.3 m in the previous year
• •Opg p enin g of four plasma collection centres in the US and Hungary to date
• •"Biotest Next Level" project is on track
• •Guidance confirmed

Worldwide sales increases

Salesby region (€ million)

• • Markets of North America and Middle East & Africa made most significant contribution to growth
• • Highest growth rates in Other Asia & Pacific
• • Decrease in Germany due to one time effect of high plasma sales in previous year period

Strong increase in EBIT

• Reduction of R&D costs to 8.5% of l sa es
• •Slightly higher gross profit
• in administrative expenses

Increase in earnings after taxes

• • Financial result at - € 4.3m(vs. -€0.2 m in H1 2015 due to currency translation effect of USD
• •Higher taxes due to good result

Financial position: strong equity base

Fi i l iti f th Bi t t G (€ illi ) Financial position of the Biotest Group million)

Cash flow from operating activities

January – June 2016 (in € million)

	H 1 2 0 1 5	H 1 2 0 1 6
O C f C i F b h i W k i i l t t p e r a n g e o r e c a n g e s n o r n g a p a	1 8 6	3 2 4
C f f C h l h i W k i i l t a s o w r o m c a n g e s n o r n g a p a	2 6 1	2 1 0
I d i d t t t n e r e s a n a e s p a x	1 3 5 -	3 8 -
C h f l f i i i i t t t a s o r o m o p e r a n g a c e s w v	3 1 2	4 9 6

Other issues

• •Investigation Russia ongoing
• •New tax assessment for years 2005 – 2008
• •Uncertainty g with regard to some Bivigam® batch releases by FDA

Positive development of key figures Sales, operating cash flow, EBITDA, EBIT

Guidance 2016 confirmed

• Sales: In the financial year 2016 sales will grow in a low single-digit percentage range
• EBIT:EBIT in the range of € 33-35 million

Financial Calendar 2016 / 2017Contact Financial Calendar 2016 / 201710 Nov 2016 9M Report 2016 30 M 2017 Mar FY R t 2016 Report 11 May 2017 Annual Shareholder Meeting 11 May 2017 3M Report 2017 14 Aug 2017 6M Report 2017 Investor Relations Public RelationsDr. Monika Buttkereit Dirk Neumüller 14 Nov 2017 9M Report 2017 Tel.: +49-6103-801-4406 Tel.: +49-6103-801-269investor_relations@biotest.de pr@biotest.de